Drug Profile
Thrombosis inhibitor - Bayer HealthCare Pharmaceuticals
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Bayer Schering Pharma
- Developer Bayer HealthCare Pharmaceuticals
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Disseminated intravascular coagulation
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Disseminated-intravascular-coagulation in Unknown
- 01 Mar 2011 Bayer Schering Pharma is now called Bayer HealthCare Pharmaceuticals
- 31 Jan 2010 Phase-I clinical trials in Disseminated intravascular coagulation (unspecified route)